• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
CAT ASCOT Atenolol and NOD

CAT ASCOT Atenolol and NOD



My First Practice-Altering CAT. And I'm not even in practice yet!

My First Practice-Altering CAT. And I'm not even in practice yet!



Total Views
Views on SlideShare
Embed Views



2 Embeds 41

http://notmysecondopinion.blogspot.com 34
http://notmysecondopinion.blogspot.com.au 7



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

CC Attribution-ShareAlike LicenseCC Attribution-ShareAlike License

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    CAT ASCOT Atenolol and NOD CAT ASCOT Atenolol and NOD Presentation Transcript

    • CAT: Atenolol and New-Onset Diabetes Mellitus Clinton Pong IM Journal Club 4/2/09
    • My Clinical Question
      • “ Is Atenolol associated with new-onset diabetes mellitus (NOD) in patients with significant cardiovascular risk factors?
      • “ CV RF”
        • 55+ y/o
        • Male
        • smoker
        • LVH
        • EKG abnormalities
        • DM II
        • PAD
        • PMH Stroke/TIA
        • Microalbuminuria/proteinuria
        • Tchol:HDL >6
        • FHx of premature CHD
    • Search
    • Source ASCOT Trial: CCB (Amlodipine) vs BB (Atenolol)
    • Validity?
      • Randomized
      • Accountable
      • Intention to treat analysis
      • Similar groups
      • Sponsored by Pfizer, Servier, and Leo Pharmaceuticals
    • Population Goal: 18,000 Recruited:19,257 Final study pop: 18,965 Intervention Comparison Amlodipine Atenolol + Perindopril + Bendroflumethiazide (n=9639) (n=9618)
    • 567 799 9072 8819 CV endpoints NOD 5.5 years Amlodipine Atenolol NOD (+) No NOD
    • Results
      • total cardiovascular events and procedures
      • Kaplan-Meier curves of cumulative incidence of new-onset diabetes mellitus
      NNH: 40 NNH: 42
    • Care of my patient
      • Atenolol’s effectiveness in the prevention of CV disease has been called into question by numerous other studies
      • No long-term comparative effectiveness studies compare it to other beta blockers
      • Regarded as an “atypical beta blocker”
    • Summary statement:
      • I do believe that the results suggest that Atenolol is an inferior choice for the initial treatment of HTN in the prevention of CV disease and new-onset diabetes compared to Amlodipine and I recommend that our patients switch to this drug today.
    • Resources
      • Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
        • Dahlöf B, et al. Lancet. 2005 Sep 10-16;366(9489):895-906.
      • The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm. (ASCOT)
        • J Clin Pharm Ther. 2006 Aug;31(4):299-307